(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of 67.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Dianthus Therapeutics's revenue in 2025 is $5,366,000.On average, 5 Wall Street analysts forecast DNTH's revenue for 2025 to be $172,313,530, with the lowest DNTH revenue forecast at $118,387,860, and the highest DNTH revenue forecast at $257,197,626. On average, 4 Wall Street analysts forecast DNTH's revenue for 2026 to be $168,317,940, with the lowest DNTH revenue forecast at $59,193,930, and the highest DNTH revenue forecast at $257,197,626.
In 2027, DNTH is forecast to generate $868,878,102 in revenue, with the lowest revenue forecast at $59,193,930 and the highest revenue forecast at $1,668,084,947.